Oral insulin 338 (I338) can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine. The evidence for its feasibility has been published for the first time in The Lancet Diabetes & Endocrinology online. I338 is a long-acting, basal insulin analog formulated in a tablet with the absorption-enhancer sodium caprate.
Updated AHA/ACC/HRS treatment guidelines for atrial fibrillation (AF) recommend a newer type of blood-thinning medications, non-vitamin K oral anticoagulants (NOACs) as the preferred alternative to warfarin for reducing the risk of stroke associated with AF. Sudden cardiac death remains a daunting problem for at least three major reasons: (i) With a prevalence of 20% of total mortality in the industrial world it has a major impact on society; (ii) It has devastating psycho-social effects on…
